Q4 2024 Management View CEO Jennifer Ernst highlighted significant advancements, including the acquisition of exclusive worldwide rights to the Phase III immunomodulatory drug candidate Entolimod, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback